Growth Outcomes and Relapse Risk in Pediatric Medulloblastoma Survivors with and Without Growth Hormone Therapy: A 23-Year Single-Center Cohort Study
Journal of Clinical Medicine · 01.05.2026 · 15 (9) · 3472
DOI: 10.3390/jcm15093472 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Clinical Medicine, online erschienen am 01.05.2026. Verfasst von Gerdi Tuli und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Endocrinology, Regina Margherita Children's Hospital, 10126 Turin, Italy. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Growth hormone deficiency (GHD) is one of the most common endocrine sequelae in survivors of pediatric medulloblastoma, largely resulting from hypothalamic–pituitary irradiation. Concerns regarding the oncologic safety of growth hormone (GH) replacement have historically limited its use. This study aimed to evaluate growth response to GH therapy and its potential association with tumor relapse in medulloblastoma survivors treated between 2000 and 2023.
Methods
We conducted a retrospective single-center cohort study including 74 patients diagnosed with medulloblastoma before 18 years of age. GHD was confirmed by stimulation testing according to standard criteria. Auxological, endocrine, and oncologic data were collected longitudinally. Growth outcomes were compared among patients without GHD (n = 38), patients with untreated GHD (n = 13), and patients with GHD receiving GH treatment (n = 23). Relapse rates were assessed following GH initiation and compared with those of untreated patients.
Results
GHD was diagnosed in 48.7% of patients. Baseline height SDS did not differ among groups. Patients with untreated GHD experienced a significant decline in height SDS (−1.93 ± 0.78), whereas GH-treated patients showed a significant increase (+0.39 ± 0.06; p < 0.0001). Final height SDS was significantly lower in untreated GHD patients (−2.45 ± 0.36) compared with GH-treated patients (−1.71 ± 0.68) and patients without GHD (−0.68 ± 0.24; p < 0.0001). No evidence of an increased risk of tumor relapse was observed in association with GH therapy during follow-up.
Conclusions
GH replacement significantly improves growth outcomes in medulloblastoma survivors with confirmed GHD without apparent increase in relapse risk when initiated after stable remission. The early identification and multidisciplinary management of GHD are essential components of long-term survivorship care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatric Endocrinology, Regina Margherita Children's Hospital, 10126 Turin, Italy.
- Department of Pediatric and Public Health Sciences, University of Turin, 10124 Turin, Italy.
- Department of Pediatric Neurosurgery, Regina Margherita Children's Hospital, 10126 Turin, Italy.
- Pediatric Onco-Hematology, Stem Cell Transplantation and Cellular Division, Regina Margherita Children's Hospital, 10126 Turin, Italy.
- Oncological Endocrinology, Department of Oncology, AOU Città Della Salute e Della Scienza, 10126 Turin, Italy.
- Radiotherapy Unit, Regina Margherita Children's Hospital, 10126 Turin, Italy.
ORCID-Profile: Gerdi Tuli, Franca Fagioli, Luisa De Sanctis
Zitieren
APA
Tuli, G., Munarin, J., Ragazzi, P., Biasin, E., Felicetti, F., Mussano, A., Vallero, S. G., Bertin, D., Peretta, P., Morana, G., Fagioli, F., & De Sanctis, L. (2026). Growth Outcomes and Relapse Risk in Pediatric Medulloblastoma Survivors with and Without Growth Hormone Therapy: A 23-Year Single-Center Cohort Study. Journal of Clinical Medicine, 15(9), 3472. https://doi.org/10.3390/jcm15093472
Vancouver
Tuli G, Munarin J, Ragazzi P, Biasin E, Felicetti F, Mussano A, et al. Growth Outcomes and Relapse Risk in Pediatric Medulloblastoma Survivors with and Without Growth Hormone Therapy: A 23-Year Single-Center Cohort Study. Journal of Clinical Medicine. 2026;15(9):3472. doi:10.3390/jcm15093472
BibTeX
@article{Tuli2026,
author = {Tuli, Gerdi and Munarin, Jessica and Ragazzi, Paola and Biasin, Eleonora and Felicetti, Francesco and Mussano, Anna and Vallero, Stefano Gabriele and Bertin, Daniele and Peretta, Paola and Morana, Giovanni and Fagioli, Franca and De Sanctis, Luisa},
title = {Growth Outcomes and Relapse Risk in Pediatric Medulloblastoma Survivors with and Without Growth Hormone Therapy: A 23-Year Single-Center Cohort Study},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {9},
pages = {3472},
doi = {10.3390/jcm15093472}
}
EUVIMED